ChondroFiller injection versus knee replacement for focal defectsChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
ChondroFiller™ durability compared with ArthrosamidChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.ChondroFiller™ recruits the patient's own progenitor cells to build new cartilage tissue within a collagen scaffold. Three-year published follow-up shows mean IKDC scores of 80 — a 32.4-point improvement from baseline — with durability reported to extend beyond five years.
ChondroFiller injection cost in the UKChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.ChondroFiller injection costs £3,000–£9,800 depending on cartilage defect size; the NHS does not fund it, and quoted prices bundle assessment, imaging, injection, and six-week follow-up.
ChondroFiller injection for knee cartilage defectsThe injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.The injected collagen scaffold gels in place and recruits the body's own progenitor cells to repair the cartilage defect without surgery or general anaesthetic. Functional scores improve from 48 to 80 on the IKDC scale over three years in independent European cohorts, with most of that improvement within six months.
Medial knee pain that isn't a meniscus tearAround 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.Around 850,000 meniscal surgeries are performed annually in the United States, yet five other structures in the medial knee generate pain so similar that clinicians commonly mistake them for meniscal tears.
What separates ChondroFiller from Liquid CartilageChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.ChondroFiller is a single collagen scaffold delivered two ways: as an outpatient injection alone, or combined with patient-derived cells under the clinical brand Liquid Cartilage™. Naming overlap at clinics obscures which is being offered.
ChondroFiller for focal knee defects versus early osteoarthritisFocal cartilage defects and early osteoarthritis produce identical symptoms but differ structurally — a contained lesion versus compartment-wide degeneration — and imaging determines which pathway applies. ChondroFiller, an injectable collagen scaffold into which the body's progenitor cells migrate and lay down new cartilage tissue, addresses only focal lesions.Focal cartilage defects and early osteoarthritis produce identical symptoms but differ structurally — a contained lesion versus compartment-wide degeneration — and imaging determines which pathway applies. ChondroFiller, an injectable collagen scaffold into which the body's progenitor cells migrate and lay down new cartilage tissue, addresses only focal lesions.
The cost of leaving a knee cartilage defect untreatedKnee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.Knee cartilage defects do not heal because cartilage lacks blood supply; defects widen under load with each step, spreading damage to surrounding tissue and progressing towards osteoarthritis if untreated.
Recovery after a ChondroFiller injectionChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.ChondroFiller works by recruiting the body's progenitor cells into a collagen scaffold to regenerate cartilage; improvement takes six to twelve weeks, not days.
What the ChondroFiller evidence actually showsChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
When cartilage repair makes sense before knee replacementTotal knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.Total knee replacement achieves over 90% long-term success, yet patients under 55 face substantially higher revision risk within 20 years. For focal cartilage damage in the mid-40s, repair offers a joint-preservation pathway suited to this earlier disease stage—provided defect size and patient profile meet defined clinical criteria.